Cellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational Progress

Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced business highlights and financial results for the fiscal year ended December 31, 2017.

As quoted in the press release:

“2017 was a pivotal year for CBMG and for the cell therapy environment. The U.S. Food and Drug Administration (FDA) had approved the first two chimeric antigen receptor T cell (CAR-T) therapies that use a patient’s own T cells to fight cancer. The issuance in December 2017 of China’s CFDA Guiding Principles for the Research and Evaluation of Cell Therapy Products provides a clear path for CBMG to advance our pipeline from clinical development to commercialization.  We have initiated our CAR-T clinical trials and have been recruiting patients. We opened our new state-of-the-art GMP manufacturing facility in Shanghai’s Pharma Valley and signed strategic partnerships with GE Healthcare Life Sciences China and Thermo Fisher Scientific China to focus on improving manufacturing processes for cell therapies,” said Tony (Bizuo) Liu, CEO of the Company.

Click here to read the full press release.